The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic ...

Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three ...

The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...

Biopharmaceutical company UCB has received US Food and Drug Administration (FDA) approval for BIMZELX (bimekizumab-bkzx) to ...

UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx), an ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

The European Commission has cleared the drug as Bimzelx for the treatment of moderate to severe plaque psoriasis in adults, which is its first regulatory approval worldwide and comes six years ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

One in four participants in a European wide study aimed at detecting early signs of psoriasis showed signs of possible arthritis. There are racial differences in the frequency of skin biopsy for ...

The drug, also known as bimekizumab-bkzx, is already approved for the treatment of moderate-to-severe plaque psoriasis. Bimzelx is designed to selectively inhibit IL-17A and IL-17F, two key ...

Bimzelx is now approved for the treatment of adult patients with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. The Food and Drug Administration (FDA ...